Quantitative systems pharmacology

Computational Biology Market size worth $ 12.45 Billion, Globally, by 2028 at 20.64% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, March 15, 2022
Computational biology, Pharmacokinetics, Commercial, Generate, Proteomics, Immunotherapy, Genomics, Immunogenicity, Quantitative systems pharmacology, Drug discovery, Geography, Compugen, Checkpoint, SAS, Animal, CAGR, Association, Investment, USD, EMT, Cell, Drug development, NIEHS, BIOVIA, Research, Probability, Growth, Engineering, QSP, Market research, Biology, DNA, Systems pharmacology, Pharmaceutical industry, Industry, Entelo

JERSEY CITY, N.J., March 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Computational Biology Market" By End-User (Industry, Commercial, Academics), By Application (Preclinical Drug Development, Human Body Simulation Software, Drug Discovery & Disease Modelling), and By Geography. According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.

Key Points: 
  • JERSEY CITY, N.J., March 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Computational Biology Market " By End-User (Industry, Commercial, Academics), By Application (Preclinical Drug Development, Human Body Simulation Software, Drug Discovery & Disease Modelling), and By Geography.
  • According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.
  • In the areas of genomics, proteomics, pharmacogenomics, and drug development, computational biology offers a wide range of applications.
  • Verified Market Research has segmented the Global Computational Biology Market On the basis of End-User, Application, and Geography.

U.S. FDA Licenses Certara’s Immunogenicity Simulator

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Risk, Therapy, Partnership, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, QSP, Quantitative systems pharmacology, Drug development, IG, Doctor of Pharmacy, Food, FDA, Nasdaq, Drug discovery, Patient, Simulation, Technology, Research, MIDD, Vaccine, Medical device, Certara

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certaras Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics.

Key Points: 
  • PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certaras Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics.
  • Certaras IG Simulator predicts the immune response of therapeutics in development, which is important to guide clinical and regulatory decision-making.
  • Certaras IG Simulator is used to assess, predict and manage immunogenicity of a wide range of biologics, including monoclonal antibodies, bi-and multi-specifics and cell and gene therapies.
  • The IG Simulator was developed in partnership with eight leading pharmaceutical companies in Certaras IG QSP Consortium.

Applied BioMath, LLC Announces Participation at the Cytokine-Based Cancer Immunotherapies Summit

Retrieved on: 
Monday, November 29, 2021
Patient, Pharmacology, CEO, PD, Industry, Biology, Disease, Doctor of Philosophy, Solution, Applied psychology, Therapy, VP, Quantitative biology, Software, Machine learning, R, Research, LLC, Biotechnology, Quantitative systems pharmacology, Knowledge, QSP, Medical device

In the presentation, Dr. Hua will discuss how QSP models can be used to help understand pharmacokinetic (PK) and pharmacodynamic (PD) complexities of immunocytokines and accelerate R&D.

Key Points: 
  • In the presentation, Dr. Hua will discuss how QSP models can be used to help understand pharmacokinetic (PK) and pharmacodynamic (PD) complexities of immunocytokines and accelerate R&D.
  • "Understanding complex modalities such as immunocytokines is extremely resource intensive and difficult to do without the use of mathematical models," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • For more information about Applied BioMath and its services and software, visit www.appliedbiomath.com .
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Retrieved on: 
Monday, October 25, 2021
Science, Clinical pharmaceutical scientist, Technology, Vaccine, US, Association, Pharmacology, Vaccination, Quantitative systems pharmacology, COVID-19 vaccine, Drug discovery, Doctor of Pharmacy, COVID-19, R, American College of Clinical Pharmacy, American College, Nasdaq, American Association, AAPS, University of Oxford, GLOBE, Doctor of Philosophy, ACCP, Pharmaceutical industry

PRINCETON, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 R&D pioneers and their revolutionary ideas in science and technology in the past year.

Key Points: 
  • PRINCETON, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 R&D pioneers and their revolutionary ideas in science and technology in the past year.
  • The model, which is incorporated in Certaras Vaccine Simulator, has been used by major pharmaceutical companies and allows researchers to study how a vaccine is handled by the human body in computer-generated, virtual populations.
  • Certaras Simcyp COVID-19 Vaccine Model has demonstrated that it can accurately predict the outcomes of actual clinical trials using COVID-19 vaccines.
  • Certara calibrated its model using COVID-19 vaccine structures and validated it by replicating the published clinical data.

InSysBio to launch its OpenSource HetaSimulator project

Retrieved on: 
Wednesday, August 11, 2021
CEO, Solution, JavaScript, Quantitative systems pharmacology, Environment, QSP, Systems biology, Doctor of Philosophy, Open source, Employment Development Department, Medical device

MOSCOW, Aug. 11, 2021 /PRNewswire/ -- InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents HetaSimulator.

Key Points: 
  • MOSCOW, Aug. 11, 2021 /PRNewswire/ -- InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents HetaSimulator.
  • HetaSimulator is a simulation and parameters estimation platform for the Heta modeling language and a component of Heta project .
  • I believe Heta project is the most functional and flexible environment to develop a modeling project or advisory applications."
  • Oleg Demin, PhD, CEO of InSysBio, highlights the significance of the innovation, "The launch of HetaSimulator is a crucial step of a strategic goal to build full circle QSP modeling infrastructure.

Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)

Retrieved on: 
Thursday, June 17, 2021
Data management, Health, Technology, Software, Pharmaceutical, Biotechnology, Medicine, Health sciences, Clinical medicine, Lung disorders, Simulation software, Simulations Plus, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Simulation, Quantitative systems pharmacology, IPF, Fibrosis

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis.
  • IPF is the most common type of pulmonary fibrosis, a disease that causes scarring (fibrosis) of the lungs.
  • The combination of IPFsym and our scientific consulting expertise is positioned to support our clients in this important field.
  • Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

Simulations Plus Enters Agreement with Distributor in China

Retrieved on: 
Tuesday, February 2, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, Health sciences, Life sciences, Health, Pharmaceutical industry, Contract research organizations, Simulation software, Simulations Plus, Clinical research, Simulation, Modeling and simulation, Quantitative systems pharmacology, Cytel

Founded in 2015, Mosim was the first clinical contract research organization (CRO) providing clinical pharmacology services in China.

Key Points: 
  • Founded in 2015, Mosim was the first clinical contract research organization (CRO) providing clinical pharmacology services in China.
  • Working with Lixoft will allow us to provide Chinas pharmaceutical scientists with a powerful tool for population PK/PD modeling.
  • Also, as a leading provider of modeling and simulation in China, Mosim is committed to training young clinical pharmacologists and pharmacometricians, and MonolixSuite will contribute significantly to this important work.
  • Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting

Retrieved on: 
Thursday, December 3, 2020
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Health care, Pharmacology, Quantitative systems pharmacology, Antivirals, Orphan drugs, Simulations Plus, Antibody, Remdesivir, American Association for the Study of Liver Diseases, Fibroblast growth factor receptor 1, DILIsym Services, Inc., Simulations Plus, Inc.

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applications of their software programs were presented in poster form at the 2020 AASLD virtual Liver Meeting.

Key Points: 
  • DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applications of their software programs were presented in poster form at the 2020 AASLD virtual Liver Meeting.
  • Liver safety research conducted with the DILIsym software platform was reported for the COVID-19 drug remdesivir in a poster presented by Dr. Kyunghee Yang.
  • Quantitative systems pharmacology (QSP) work was presented by Dr. Zack Kenz focused on a NAFLDsym software application for the agonist anti-FGFR1/KLB bispecific antibody, BFKB8488A .
  • DILIsym modeling supports key drug development decisions by predicting potential drug-induced liver injury (DILI) risk of new drug candidates.

Lixoft Expands MonolixSuite™ in Version 2020R1

Retrieved on: 
Tuesday, November 3, 2020
Consulting, Data management, Biotechnology, Technology, Professional services, Health, Pharmaceutical, Research, Software, Science, Clinical trials, Health sciences, Pharmaceutical sciences, Simulation software, Life sciences, Modeling and simulation, Pharmacology, Quantitative systems pharmacology, Simulation, Pharmacokinetics, Alternatives to animal testing, Pharmacometrics, Lixoft, Simulations Plus, Inc.

Lixoft , a Simulations Plus company (Nasdaq: SLP), a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, today announced that it has released version 2020R1 of its MonolixSuite .

Key Points: 
  • Lixoft , a Simulations Plus company (Nasdaq: SLP), a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, today announced that it has released version 2020R1 of its MonolixSuite .
  • Key advancements in MonolixSuite version 2020R1 include:
    An enhanced Simulx module with a graphical user interface (GUI) featuring:
    A simulation section allowing simulations of populations and clinical trials, post-processing to outcomes and endpoints, and replicates for uncertainty assessment.
  • Jonathan Chauvin , Lixoft deputy general manager, said: This is a significant breakthrough for the platform, especially for simulation purposes.
  • With our subsidiaries, Cognigen , DILIsym Services , and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches.

InSysBio announces its collaboration with Genmab

Retrieved on: 
Wednesday, September 23, 2020
Pharmacology, Health, Articles, Life sciences, Quantitative systems pharmacology, Genmab, QSP, BioNTech, Systems pharmacology, Monoclonal antibody therapy

MOSCOW andPRINCETON, N.J., Sept. 23, 2020 /PRNewswire/ -- InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Key Points: 
  • MOSCOW andPRINCETON, N.J., Sept. 23, 2020 /PRNewswire/ -- InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
  • Genmab, in partnership with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody-CD40x4-1BB), for solid tumors.
  • Oleg Demin, CEO of InSysBio, highlights: "The project with Genmab represents ideal case for application of QSP modeling approach.
  • InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED).